Page last updated: 2024-08-21
diphenylamine and pf 00299804
diphenylamine has been researched along with pf 00299804 in 1 studies
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Beijnen, JH; Bernards, R; de Vos, FYFL; Devriese, LA; Eskens, FALM; Huijberts, SCFA; Huitema, ADR; Lolkema, MPJK; Marchetti, S; Monkhorst, K; Opdam, FL; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM | 1 |
Trials
1 trial(s) available for diphenylamine and pf 00299804
Article | Year |
---|---|
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diphenylamine; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolinones | 2020 |